Immunization with hepatitis B vaccine accelerates SLE-like disease in a murine model

Journal of Autoimmunity

Volumn 54, Issue , 2014, Pages 21-32

  Agmon Levin, Nancy ^a,b   Arango, María Teresa ^a,c   Kivity, Shaye ^a,b   Katzav, Aviva ^a   Gilburd, Boris ^a   Blank, Miri ^a   Tomer, Nir ^a   Volkov, Alex ^a   Barshack, Iris ^a   Chapman, Joab ^a   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSIDAD DEL ROSARIO   (Colombia)

Author keywords

Autoimmune autoinflammatory syndrome induced by adjuvant (ASIA); Autoimmunity; Hepatitis B vaccine; Neuro cognitive tests; SLE; Vaccination

Indexed keywords

ALUMINUM HYDROXIDE; DOUBLE STRANDED DNA ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; PHOSPHATE BUFFERED SALINE; RECOMBINANT HEPATITIS B VACCINE; ANTINUCLEAR ANTIBODY; HEPATITIS B VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANXIETY; ARTICLE; AUTOIMMUNE DISEASE; BLOOD CELL COUNT; BRAIN HISTOLOGY; BRAIN REGION; CELL LINEAGE; COGNITION; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG SAFETY; ERYTHROCYTE; FEMALE; FORCED SWIM TEST; GLIOSIS; IMMUNIZATION; KIDNEY DISEASE; LUPUS LIKE SYNDROME; MEMORY DISORDER; MICROGLIA; MOUSE; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; PROTEINURIA; STAIRCASE TEST; SYSTEMIC LUPUS ERYTHEMATOSUS; Y-MAZE TEST; ANIMAL; BRAIN; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ANTIBODIES, ANTINUCLEAR; BRAIN; COGNITION; DISEASE MODELS, ANIMAL; FEMALE; HEPATITIS B VACCINES; LUPUS NEPHRITIS; MICE; PROTEINURIA;

EID: 84908495912     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.06.006     Document Type: Article

References (93)

1. Agmon-Levin N., Paz Z., Israeli E., Shoenfeld Y. Vaccines and autoimmunity. Nature reviews Rheumatology 2009, 5:648-652.
2. Scalera N.M., Mossad S.B. The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus. Postgrad Med 2009, 121:43-47.
3. Keating G.M., Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 2003, 63:1021-1051.
4. Bijl M., Agmon-Levin N., Dayer J.M., Israeli E., Gatto M., Shoenfeld Y. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmunity reviews 2012, 11:572-576.
5. van Assen S., Agmon-Levin N., Elkayam O., Cervera R., Doran M.F., Dougados M., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422.
6. Lasky T., Terracciano G.J., Magder L., Koski C.L., Ballesteros M., Nash D., et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998, 339:1797-1802.
7. Classen J.B., Classen D.C. Clustering of cases of insulin dependent diabetes (IDDM) occurring three years after hemophilus influenza B (HiB) immunization support causal relationship between immunization and IDDM. Autoimmunity 2002, 35:247-253.
8. Mikaeloff Y., Caridade G., Suissa S., Tardieu M. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 2009, 72:873-880.
9. Agmon-Levin N., Kivity S., Szyper-Kravitz M., Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. Lupus 2009, 18:1198-1204.
10. Pellegrino P., Carnovale C., Pozzi M., Antoniazzi S., Perrone V., Salvati D., et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmunity reviews 2014, 13:736-741.
11. Lind A., Ramelius A., Olsson T., Arnheim-Dahlstrom L., Lamb F., Khademi M., et al. A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010. Journal of autoimmunity 2014, 50:99-106.
12. Older S.A., Battafarano D.F., Enzenauer R.J., Krieg A.M. Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Seminars in arthritis and rheumatism 1999, 29:131-139.
13. Agmon-Levin N., Zafrir Y., Paz Z., Shilton T., Zandman-Goddard G., Shoenfeld Y. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus 2009, 18:1192-1197.
14. Murdaca G., Orsi A., Spano F., Puppo F., Durando P., Icardi G., et al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmunity reviews 2014, 13:75-84.
15. Mok C.C., Ho L.Y., Fong L.S., To C.H. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013, 72:659-664.
16. Soldevilla H.F., Briones S.F., Navarra S.V. Systemic lupus erythematosus following HPV immunization or infection?. Lupus 2012, 21:158-161.
17. Gatto M., Agmon-Levin N., Soriano A., Manna R., Maoz-Segal R., Kivity S., et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013, 32:1301-1307.
18. Shoenfeld Y., Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. Journal of autoimmunity 2011, 36:4-8.
19. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PloS one 2012, 7. 1e33536-9 e33536.
20. Stubgen J.P. Immune-mediated myelitis following hepatitis B vaccination. Autoimmunity reviews 2012, 12:144-149.
21. Zafrir Y., Agmon-Levin N., Paz Z., Shilton T., Shoenfeld Y. Autoimmunity following hepatitis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): analysis of 93 cases. Lupus 2012, 21:146-152.
22. Bruzzese V., Zullo A., Hassan C. Connective tissue disease following hepatitis B vaccination. J Clin Rheumatol 2013, 19:280-281.
23. Kivity S., Agmon-Levin N., Blank M., Shoenfeld Y. Infections and autoimmunity-friends or foes?. Trends in immunology 2009, 30:409-414.
24. Tomljenovic L., Shaw C.A. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus 2012, 21:223-230.
25. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18:1217-1225.
26. Shaw C.A., Petrik M.S. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. Journal of inorganic biochemistry 2009, 103:1555-1562.
27. Perricone C., Colafrancesco S., Mazor R.D., Soriano A., Agmon-Levin N., Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. Journal of autoimmunity 2013, 47:1-16.
28. Sundberg J.P., Silva K.A., Zhang W., Sundberg B.A., Edwards K., King L.E., et al. Recombinant human hepatitis B vaccine initiating alopecia areata: testing the hypothesis using the C3H/HeJ mouse model. Vet Dermatol 2009, 20:99-104.
29. Cruz-Tapias P., Agmon-Levin N., Israeli E., Anaya J.M., Shoenfeld Y. Autoimmune (auto-inflammatory) syndrome induced by adjuvants (ASIA)-animal models as a proof of concept. Curr Med Chem 2013, 20:4030-4036.
30. Leiss H., Niederreiter B., Bandur T., Schwarzecker B., Bluml S., Steiner G., et al. Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation. Lupus 2013, 22:778-792.
31. Xu Y., Zeumer L., Reeves W.H., Morel L. Induced murine models of systemic lupus erythematosus. Methods Mol Biol 2014, 1134:103-130.
32. Shoenfeld Y., Rauova L., Gilburd B., Kvapil F., Goldberg I., Kopolovic J., et al. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. International immunology 2002, 14:1303-1311.
33. Bakimer R., Fishman P., Blank M., Sredni B., Djaldetti M., Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 1992, 89:1558-1563.
34. Tordera R.M., Totterdell S., Wojcik S.M., Brose N., Elizalde N., Lasheras B., et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci 2007, 25:281-290.
35. Dix S.L., Aggleton J.P. Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition. Behav Brain Res 1999, 99:191-200.
36. Simiand J., Keane P.E., Morre M. The staircase test in mice: a simple and efficient procedure for primary screening of anxiolytic agents. Psychopharmacology (Berl) 1984, 84:48-53.
37. Shrot S., Katzav A., Korczyn A.D., Litvinju Y., Hershenson R., Pick C.G., et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus 2002, 11:736-743.
38. Katzav A., Pick C.G., Korczyn A.D., Oest E., Blank M., Shoenfeld Y., et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus 2001, 10:496-499.
39. Katzav A., Kivity S., Blank M., Shoenfeld Y., Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus 2012, 21:210-216.
40. Katzav A., Solodeev I., Brodsky O., Chapman J., Pick C.G., Blank M., et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis and rheumatism 2007, 56:938-948.
41. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
42. Wang Z., Li M., Zeng X., Liu X. Hepatitis B virus-associated antigen deposition in renal tissue from patients with systemic lupus erythematosus. The Journal of rheumatology 2012, 39:974-978.
43. Yu C., Gershwin M.E., Chang C. Diagnostic criteria for systemic lupus erythematosus: A critical review. Journal of autoimmunity 2014, 48-49C:10-13.
44. Santoro D., Vita G., Vita R., Mallamace A., Savica V., Bellinghieri G., et al. HLA haplotype in a patient with systemic lupus erythematosus triggered by hepatitis B vaccine. Clinical nephrology 2010, 74:150-153.
45. Thomas C., Moridani M. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology 2010, 278:204-210.
46. Santoro D., Stella M., Montalto G., Castellino S. Lupus nephritis after hepatitis B vaccination: an uncommon complication. Clinical nephrology 2007, 67:61-63.
47. Marinchev L., Antonov K., Peytcheva V., Kolarov Z. Outcome in a patient with systemic lupus erythematosus and concurrent chronic hepatitis B infection. BMJ case reports 2010, 2010.
48. Pennesi M., Torre G., Del Santo M., Sonzogni A. Glomerulonephritis after recombinant hepatitis B vaccine. The Pediatric infectious disease journal 2002, 21:172-173.
49. Venkataseshan V.S., Lieberman K., Kim D.U., Thung S.N., Dikman S., D'Agati V., et al. Hepatitis-B-associated glomerulonephritis: pathology, pathogenesis, and clinical course. Medicine 1990, 69:200-216.
50. Lai F.M., To K.F., Wang A.Y., Choi P.C., Szeto C.C., Li P.K., et al. Hepatitis B virus-related nephropathy and lupus nephritis: morphologic similarities of two clinical entities. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2000, 13:166-172.
51. Zagoria R.J., T G. Genitourinary Radiology: The Requisites 1997, 139-140. Chapter 4.
52. Newman K., Owlia M.B., El-Hemaidi I., Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus - Old and new. Autoimmunity reviews 2013, 12:784-791.
53. Turgut S., Bor-Kucukatay M., Emmungil G., Atsak P., Turgut G. The effects of low dose aluminum on hemorheological and hematological parameters in rats. Archives of toxicology 2007, 81:11-17.
54. Farina M., Lara F.S., Brandao R., Jacques R., Rocha J.B. Effects of aluminum sulfate on erythropoiesis in rats. Toxicology letters 2002, 132:131-139.
55. Ganchev T., Dyankov E., Zacharieva R., Pachalieva I., Velikova M., Kavaldjieva B. Influence of aluminium on erythropoiesis, iron metabolism and some functional characteristics of erythrocytes in rats. Acta physiologica et pharmacologica Bulgarica 1998, 23:27-31.
56. Unterman A., Nolte J.E., Boaz M., Abady M., Shoenfeld Y., Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Seminars in arthritis and rheumatism 2011, 41:1-11.
57. Hanly J.G. Diagnosis and management of neuropsychiatric SLE. Nature reviews Rheumatology 2014, 10:338-347.
58. Zandman-Goddard G., Chapman J., Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Seminars in arthritis and rheumatism 2007, 36:297-315.
59. Mahler M., Agmon-Levin N., van Liempt M., Shoenfeld Y., Waka A., Hiepe F., et al. Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope. Rheumatology international 2012, 32:691-698.
60. Kivity S., Tsarfaty G., Agmon-Levin N., Blank M., Manor D., Konen E., et al. Abnormal olfactory function demonstrated by manganese-enhanced MRI in mice with experimental neuropsychiatric lupus. Annals of the New York Academy of Sciences 2010, 1193:70-77.
61. Sherman G.F., Galaburda A.M., Behan P.O., Rosen G.D. Neuroanatomical anomalies in autoimmune mice. Acta neuropathologica 1987, 74:239-242.
62. Sakic B., Szechtman H., Keffer M., Talangbayan H., Stead R., Denburg J.A. A behavioral profile of autoimmune lupus-prone MRL mice. Brain, behavior, and immunity 1992, 6:265-285.
63. Sakic B., Szechtman H., Denburg J.A. Neurobehavioral alterations in autoimmune mice. Neuroscience and biobehavioral reviews 1997, 21:327-340.
64. Vogelweid C.M., Wright D.C., Johnson J.C., Hewett J.E., Walker S.E. Evaluation of memory, learning ability, and clinical neurologic function in pathogen-free mice with systemic lupus erythematosus. Arthritis and rheumatism 1994, 37:889-897.
65. Kier A.B. Clinical neurology and brain histopathology in NZB/NZW F1 lupus mice. Journal of comparative pathology 1990, 102:165-177.
66. Moore P.M. Evidence for bound antineuronal antibodies in brains of NZB/W mice. Journal of neuroimmunology 1992, 38:147-154.
67. Bracci-Laudiero L., Aloe L., Lundeberg T., Theodorsson E., Stenfors C. Altered levels of neuropeptides characterize the brain of lupus prone mice. Neuroscience letters 1999, 275:57-60.
68. Lapter S., Marom A., Meshorer A., Elmann A., Sharabi A., Vadai E., et al. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide. Arthritis and rheumatism 2009, 60:3744-3754.
69. Zardi E.M., Taccone A., Marigliano B., Margiotta D.P., Afeltra A. Neuropsychiatric systemic lupus erythematosus: Tools for the diagnosis. Autoimmunity reviews 2014, 13:831-839.
70. Postal M., Costallat L.T., Appenzeller S. Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management. CNS drugs 2011, 25:721-736.
71. Trysberg E., Nylen K., Rosengren L.E., Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis and rheumatism 2003, 48:2881-2887.
72. Hocine M.N., Farrington C.P., Touze E., Whitaker H.J., Fourrier A., Moreau T., et al. Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. Vaccine 2007, 25:5938-5943.
73. Hernan M.A., Jick S.S., Olek M.J., Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004, 63:838-842.
74. Kulkarni P.S., Sapru A., Bavdekar A., Naik S.S., Patwardhan M., Barde P., et al. Immunogenicity of two diphtheria-tetanus-whole cell pertussis-hepatitis B vaccines in infants: a comparative trial. Human vaccines 2011, 7:941-944.
75. Bogdanos D.P., Smith H., Ma Y., Baum H., Mieli-Vergani G., Vergani D. A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clinical & developmental immunology 2005, 12:217-224.
76. Israeli E., Agmon-Levin N., Blank M., Chapman J., Shoenfeld Y. Guillain-Barre syndrome-a classical autoimmune disease triggered by infection or vaccination. Clinical reviews in allergy & immunology 2012, 42:121-130.
77. Agmon-Levin N., Blank M., Paz Z., Shoenfeld Y. Molecular mimicry in systemic lupus erythematosus. Lupus 2009, 18:1181-1185.
78. Exley C., Siesjo P., Eriksson H. The immunobiology of aluminium adjuvants: how do they really work?. Trends in immunology 2010, 31:103-109.
79. Shaw C.A., Tomljenovic L. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. Immunologic research 2013, 56:304-316.
80. Flach T.L., Ng G., Hari A., Desrosiers M.D., Zhang P., Ward S.M., et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nature medicine 2011, 17:479-487.
81. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature immunology 2008, 9:847-856.
82. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nature immunology 2011, 12:509-517.
83. Wu Z., Du Y., Xue H., Wu Y., Zhou B. Aluminum induces neurodegeneration andits toxicity arises from increased iron accumulation and reactive oxygenspecies (ROS) production. Neurobiology of aging 2012, 33. 199 e1-12.
84. Han S., Lemire J., Appanna V.P., Auger C., Castonguay Z., Appanna V.D. How aluminum, an intracellular ROS generator promotes hepatic and neurological diseases: the metabolic tale. Cell biology and toxicology 2013, 29:75-84.
85. Platt B., Fiddler G., Riedel G., Henderson Z. Aluminium toxicity in the rat brain: histochemical and immunocytochemical evidence. Brain research bulletin 2001, 55:257-267.
86. Abu-Taweel G.M., Ajarem J.S., Ahmad M. Neurobehavioral toxic effects of perinatal oral exposure to aluminum on the developmental motor reflexes, learning, memory and brain neurotransmitters of mice offspring. Pharmacology, biochemistry, and behavior 2012, 101:49-56.
87. Ribes D., Colomina M.T., Vicens P., Domingo J.L. Impaired spatial learning and unaltered neurogenesis in a transgenic model of Alzheimer's disease after oral aluminum exposure. Current Alzheimer research 2010, 7:401-408.
88. Walton J.R. Cognitive deterioration and associated pathology induced by chronic low-level aluminum ingestion in a translational rat model provides an explanation of Alzheimer's disease, tests for susceptibility and avenues for treatment. International journal of Alzheimer's disease 2012, 2012:914947.
89. Khan Z., Combadiere C., Authier F.J., Itier V., Lux F., Exley C., et al. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC medicine 2013, 11:99.
90. Pillai S. Rethinking mechanisms of autoimmune pathogenesis. Journal of autoimmunity 2013, 45:97-103.
91. Gershwin M.E., Shoenfeld Y. Abul Abbas: an epitome of scholarship. Journal of autoimmunity 2013, 45:1-6.
92. Invernizzi P. Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. Journal of autoimmunity 2013, 46:1-6.
93. Jamin C., Renaudineau Y., Pers J.O. Pierre Youinou: when intuition and determination meet autoimmunity. Journal of autoimmunity 2012, 39:117-120.